HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.